Halozyme Therapeutics, Inc. (HALO) Shareholders & Insider Trades
Halozyme Therapeutics shareholders at a glance
The largest holder of Halozyme Therapeutics stock is BlackRock Advisors LLC, with 12.4 million shares (10.94% of the company), worth about $1.32 billion as of September 25, 2026. The 10 largest holders together own 39.5%.
In Q2 2026, 693 institutional holdings reports listed shares worth $9.83 billion.
Insiders reported 41 transactions in the last two years: 16 sales worth $24.99 million and no purchases. The newest one on file is from October 3, 2025 (Torley Helen I, Chief Executive Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through October 3, 2025.
Halozyme Therapeutics, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Halozyme Therapeutics shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| BlackRock Advisors LLC | 12.4 million | 10.94% | $1.3B |
| Vanguard Capital Management LLC | 5.4 million | 4.71% | $570.0M |
| Vanguard Portfolio Management LLC | 5.3 million | 4.67% | $564.0M |
| State Street Corporation | 5.2 million | 4.56% | $552.0M |
| Invesco Advisers, Inc. | 3.2 million | 2.80% | $338.0M |
| Eaton Vance Management | 2.8 million | 2.50% | $302.0M |
| Boston Partners Global Investors, Inc. | 2.8 million | 2.44% | $295.0M |
| Merrill Lynch International | 2.7 million | 2.42% | $292.0M |
| Geode Capital Management LLC | 2.5 million | 2.22% | $268.0M |
| William Blair Investment Management LLC | 2.5 million | 2.21% | $267.0M |
As of September 25, 2026.
Halozyme Therapeutics institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 693 | – | $9.8B |
| Q1 2026 | 656 | – | $7.8B |
| Q4 2025 | 639 | – | $8.4B |
| Q3 2025 | 622 | – | $8.8B |
| Q2 2025 | 571 | 119.0 million | $6.1B |
| Q1 2025 | 569 | 123.0 million | $7.8B |
| Q4 2024 | 530 | 124.0 million | $5.9B |
| Q3 2024 | 528 | 130.0 million | $7.2B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Halozyme Therapeutics insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Torley Helen I | Oct 3, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 8.11 per share. | $486,600 |
| Torley Helen I | Oct 3, 2025 | Chief Executive Officer | Sale at price 68.47 - 75.69 per share. | $4.3M |
| Connaughton Bernadette M. | Oct 1, 2025 | Director | Sale at price 75.09 - 75.70 per share. | $150,481 |
| Labrosse Nicole | Sep 22, 2025 | Chief Financial Officer | Sale at price 77.83 - 78.67 per share. | $173,584 |
| Labrosse Nicole | Sep 10, 2025 | Chief Financial Officer | Conversion of Exercise of derivative security at price 12.07 - 12.49 per share. | $150,217 |
| Labrosse Nicole | Sep 10, 2025 | Chief Financial Officer | Sale at price 75.29 - 75.93 per share. | $1.5M |
| Torley Helen I | Sep 4, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 8.11 per share. | $486,600 |
| Torley Helen I | Sep 4, 2025 | Chief Executive Officer | Sale at price 72.48 - 75.22 per share. | $4.4M |
| Connaughton Bernadette M. | Sep 2, 2025 | Director | Sale at price 71.71 - 74.11 per share. | $294,736 |
| Torley Helen I | Aug 13, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 8.11 per share. | $486,600 |
| Torley Helen I | Aug 13, 2025 | Chief Executive Officer | Sale at price 63.01 - 64.83 per share. | $3.8M |
| Torley Helen I | Jul 10, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 8.11 per share. | $486,600 |
Newest 12 of 41 insider transactions in the last two years.
Questions and answers
Who owns the most Halozyme Therapeutics stock?
BlackRock Advisors LLC, with 10.94% of the company (as of September 25, 2026). Next: Vanguard Capital Management LLC (4.71%) and Vanguard Portfolio Management LLC (4.67%).
How many institutions own Halozyme Therapeutics stock?
693 institutional holdings reports listed Halozyme Therapeutics shares in Q2 2026 worth $9.83 billion.
Are Halozyme Therapeutics insiders buying or selling the stock?
In the last two years insiders reported 16 sales and no purchases (41 transactions in all); the newest on file is from October 3, 2025.
